Tosoh Bioscience Inc

CLOSEOUT LETTER Tosoh Bioscience Inc MARCS-CMS 505636 — March 25, 2020 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Recipient: Recipient Name Yoshiyuki Shindo Recipient Title President Tosoh Bioscience Inc 6000 Shoreline Ct. #101 South San Francisco , CA 94080 United States yoshiyuki.shindo@tosoh.com Issuing Office: Office of Medical Devices and Radiological Health Operations (Division 1) United States Dear Mr. Shindo: The Food and Drug Administration has completed evaluation of your firm’s corrective actions in response to our Warning Letter CIN 16-505636-19, dated August 5, 2016. Based on our evaluation, it appears that you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The Agency expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means. You may direct any questions or comments regarding this letter to Amy Cramer at amy.cramer@fda.hhs.gov or at 732-390-3822 . Sincerely, /S/ Gina M. Brackett Director Compliance Branch Office of Medical Device & Radiological Health Operations Division 1 East Office of Regulatory Affairs U.S. Food and Drug Administration cc: Dave Wurtz, Director Quality & Compliance, dave.wurtz@tosoh.com Content current as of: 03/25/2020